118 results about "Vaccine delivery" patented technology

The present invention concerns polymer particle vaccine delivery systems in which a water insoluble protein antigen, e.g. a lipidated HpaA protein, is incorporated with particles comprising a polymer matrix. The present invention also concerns a method for incorporating such a water insoluble protein antigen with a polymer matrix in order to produce a polymer particle vaccine delivery system. In addition, the invention also provides a vaccine composition comprising the polymer particle delivery system. The vaccine can be used to treat and/or reduce the risk of for example Helicobacter infection.

An apparatus and method for transdermally delivering a vaccine comprising a delivery system having (i) a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers and (ii) an ultrasonic device. In one embodiment, the vaccine is contained in a biocompatible coating that is applied to the microprojection member. In a further embodiment, the delivery system includes a gel pack having a vaccine-containing hydrogel formulation that is disposed on the microprojection member after application to the skin of a patient. In an alternative embodiment, the vaccine is contained in both the coating and the hydrogel formulation.

The present invention provides synthetic vaccines against a variety of pathogenic organisms and tumor cells in humans and other mammals based on biodegradable polymers containing polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) and immunostimulatory adjuvants. The vaccines can be formulated as a liquid dispersion of polymer particles or molecules in which are dispersed an immunostimulatory adjuvant, such as a TLR agonist, and whole protein or peptidic antigens containing MHC class I or class II epitopes derived from organism or tumor cell proteins. Methods of inducing an immune response via intracellular mechanisms to the pathogenic organism or tumor cells specific for the antigen in the invention compositions are also included.

A system and method for transdermally delivering a vaccine to a patient including an iontophoresis delivery device having a donor electrode, a counter electrode, and electric circuitry for supplying iontophoresis energy to the electrodes, and a non-electroactive microprojection member having a plurality of stratum corneum-piercing microprojections extending therefrom. The vaccine can be contained in a hydrogel formulation in an agent reservoir disposed proximate the donor electrode, in a biocompatible coating that is disposed on the microprojections or in both.

The present invention relates to methods for intradermally delivering one or more biologically active agents such as vaccines and therapeutic agents into the dermis layer of the skin of a subject to obtain systemic delivery or an immune response using a microneedle drug delivery device containing the agent to be delivered. The methods employ a microneedle device with a row of hollow microneedles. The microneedles penetrate the skin of the subject and assume an anchored state in which the microneedles are anchored in the skin and project laterally from the device. A pivotal motion is then performed with the device so that the skin in which the microneedles are engaged is lifted above the initial plane of the surface of the skin while the biologically active agent is delivered. The methods of the invention elicit increased humoral and/or cellular response as compared to conventional vaccine delivery routes, facilitating dose sparing.

A microprojection array is provided, comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a vaccine and a polymeric material. The array may have multiple layers. The vaccine may be placed in only one layer. In another embodiment of the invention, a method of preventing a disease is provided, comprising insertion into the skin of a patient an array of microprojections comprising a layer which comprises a vaccine for that disease and a polymer.

New emulsion and micelle formulations are described as are complexes of these formulations with biologically active substances. The novel formulations are different from cationic lipid vectors such as cationic liposomes in that the complexes formed between biologically active substances and the emulsion and micellar formulations of this invention are physically stable and their transfection activity is resistant to the presence of serum. These novel formulations are disclosed to be useful in areas such as gene therapy or vaccine delivery.

The present invention provides antigen delivery compositions and methods of using same to prevent or to treat cancers and other infectious diseases. More particularly, the present invention provides a lipid-protamine-DNA (LPD) vaccine delivery system and methods of using such LPD vaccine delivery system for the prevention and treatment of cancer and other infectious diseases.

The invention relates generally to the treatment and prevention of human cancer and viral diseases. More specifically, this invention relates to development of a new generation of vaccines that rely on eliciting cellular immune responses, specifically induction of cytotoxic T lymphocytes (CTL), against cancer cells and virus-infected cells via administration of a polymeric nanoparticle containing a vaccine comprising a fusion peptide or a modified peptide. Such a fusion peptide is composed of an insertion signal sequence and a peptide derived from a tumor antigen or a viral antigen, which improves antigen presentation and induces CTL with higher efficiency against cancer cells and virus-infected cells. An exemplary peptide utilized in the invention is Mart-1:27-35 peptide.

The present invention provides synthetic vaccine delivery compositions based on polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) polymers for stimulating an immune response to a variety of pathogenic organisms and tumor cells in humans and other mammals. The vaccine delivery compositions are formulated as a liquid dispersion of polymer particles or molecules including class I or class II antigen peptides derived from organism or tumor cell proteins, which are taken up by antigen presenting cells of the mammal to induce an immune response in the mammal. Methods of inducing an immune response to the pathogenic organism or tumor cells in the invention compositions are also included.

The present invention relates to methods and devices for administration of vaccines and therapeutic agents into the intradermal layer of the skin. The methods of the present invention elicit increased humoral and/or cellular response as compared to conventional vaccine delivery methods, e.g., intramuscular route. Furthermore, the methods of the present invention facilitate induction of an immune response by an amount of vaccine which is otherwise insufficient for inducing an immune response when delivered via conventional vaccine routes, e.g., intramuscular route.

Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric particle and adaptor elements which modularly couple functional elements to the particle. The modular design of these vaccine compositions, which involves flexible addition and subtraction of antigen, adjuvant, immune potentiators, molecular recognition and transport mediation elements, as well as intracellular uptake mediators, allows for exquisite control over variables that are important in optimizing an effective vaccine delivery system.

The invention relates to lipopeptide building blocks consisting of a peptide chain comprising a coiled-coil domain, linked covalently to a lipid moiety comprising long alkyl or alkenyl chains, and optionally linked to an antigen; and to helical lipopeptide bundles and synthetic virus-like particles formed by aggregation. The nanometer size and shape of these bundles and particles, their stability under aqueous physiological conditions, their chemical composition, the possibility to incorporate B- and T-cell epitopes, and their production by chemical synthesis, make them highly suitable as vaccine delivery vehicles.

The present invention discloses a medicine deliverer adopting electroperation, which improves the delivering effect of vaccinal medicines, decreases the dosage of medicines and reduces the untoward effect of medicines. In the technical scheme, the medicine deliverer adopting electroperation, which can deliver medicine into a target tissue by means of low-frequency electrical pulses, comprises a pulse-setting module, a power supply module, a microcontroller, a pulse-generating module and a load; wherein, the pulse-setting module receives an electrical pulse parameter inputted by a user; the power supply module generates a direct-current signal; the microcontroller receives the electrical pulse parameter of the pulse-setting module and outputs a control signal according to the electrical pulse parameter; the pulse-generating module receives the control signal outputted by the microcontroller and processes the direct-current signal supplied by the power supply module into an electrical pulse signal, which is then outputted; and the load receives the electrical pulse signal outputted by the pulse-generating module. The medicine deliverer adopting electroperation is applied to the field of medicinal vaccine delivery.

The present invention relates to a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides. Probiotic-derived vesicles displaying this fusion protein as well as methods of inducing an immune response using the probiotic cells or vesicles are also disclosed.

The present invention relates to a combined DNA/Protein antigen vaccine composition which includes nucleic acid molecules and a mineral-based, negatively charged adjuvant, so as to enhance the immunogenicity of the DNA vaccine efficiently, enhancing not only plasmid DNA vaccines but also providing a novel strategy for immunogenic, multivalent combined protein/DNA vaccine delivery. Preferred adjuvants are aluminum or calcium salts, in particular aluminum phosphate.

Herein-described are various methods for making a vaccine that are made of re-assembled virus like particles (VLP). First, the VLPs are disassembled into encapsidation intermediate populations. Each encapsidation intermediate population undergoes, for instance, chemical conjugation of unique peptide or nucleic moieties to form separate populations. Thereafter, a predetermined amount of each of the several (one or more) different encapsidation intermediates from the different populations is mixed and joined, forming intact VLPs, surrounding a nucleic acid core, that are composed of different encapsidation intermediate such that the reassembled VLP displays more than one peptide or nucleic acid. The nucleic acid can function either as a scaffold alone or can be engineered for the expression of an immunomodulatory protein in a eukaryotic cell.

The invention discloses a preparation method of a targeted nano vaccine based on a metal-polyphenol network structure. The preparation method comprises the following steps that mesoporous silica nanoparticles loaded with ovalbumin OVA are prepared, mannose-modified tannic acid molecules are synthesized, and the surfaces of the mesoporous silica nanoparticles loaded with the ovalbumin OVA are coated with metal-polyphenol network coatings, so that the mesoporous silica nanoparticles loaded with the OVA and with the surfaces coated with the metal-polyphenol network coatings are obtained, therefore the targeted nano-vaccine based on the metal-polyphenol network structures is obtained, and the targeted nano-vaccine is named as MS@OVA@MPN@Man. According to the preparation method, the surfaces are coated with the metal-polyphenol network coatings, so that leakage of OVA is prevented, and the lysosome escape function of the nanoparticles is increased; and meanwhile, mannose is modified on thesurface to target a mannose receptor on the surface of an immune cell, so that the uptake capacity of the cell to the mannose receptor is enhanced to improve the vaccine delivery efficiency, and the problems of targeting of the nano vaccine and lysosome escape efficiency are solved.

The invention relates to the technical field of medicine, in particular to a targeted nano-preparation modified by mannose and mannose derivatives. In order to solve technical problems, the mannose and the mannose derivatives are adopted to conduct nano-preparation modification to prepare the nano-preparation; and the prepared nano-preparation has improved targeting capability and can be applied to vaccine delivery, tumor-targeted therapies, arteriosclerosis therapies, and therapies of various inflammatory diseases and the like.